About Methyl-CpG-binding domain protein 2
Methyl-CpG-binding domain protein 2 (MBD2) is a protein
from Homo sapiens identified by UniProt accession
Q9UBB5, 411 residues long.
MolForge cross-references it against 0 known binders and
299 disease associations.
Target properties
| Protein name | Methyl-CpG-binding domain protein 2 |
| UniProt accession | Q9UBB5 |
| Gene | MBD2 |
| Organism | Homo sapiens |
| Length | 411 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (299)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.40
- mean corpuscular volume · score 0.38
- mean corpuscular hemoglobin concentration · score 0.36
- mean corpuscular hemoglobin · score 0.36
- leukocyte count · score 0.35
- neutrophil count · score 0.34
- mean reticulocyte volume · score 0.32
- neuroticism measurement · score 0.29
- myeloid white cell count · score 0.28
- multiple sclerosis · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UBB5-F1 | alphafold | PREDICTED | 67.02 | — |
Amino-acid sequence (411 residues)
MRAHPGGGRC CPEQEEGESA AGGSGAGGDS AIEQGGQGSA LAPSPVSGVR REGARGGGRG RGRWKQAGRG GGVCGRGRGR GRGRGRGRGR GRGRGRPPSG GSGLGGDGGG CGGGGSGGGG APRREPVPFP SGSAGPGPRG PRATESGKRM DCPALPPGWK KEEVIRKSGL SAGKSDVYYF SPSGKKFRSK PQLARYLGNT VDLSSFDFRT GKMMPSKLQK NKQRLRNDPL NQNKGKPDLN TTLPIRQTAS IFKQPVTKVT NHPSNKVKSD PQRMNEQPRQ LFWEKRLQGL SASDVTEQII KTMELPKGLQ GVGPGSNDET LLSAVASALH TSSAPITGQV SAAVEKNPAV WLNTSQPLCK AFIVTDEDIR KQEERVQQVR KKLEEALMAD ILSRAADTEE MDIEMDSGDE A
Explore Methyl-CpG-binding domain protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets